- Division of Translational and Clinical Sciences – DTCS
- Oncology 2 – Translational Clinical – OTC
- Study Section:
- Cancer Immunopathology and Immunotherapy – CII
Dr. Denise Shaw joined CSR in 2007 as Scientific Review Officer for the Drug Discovery and Molecular Pharmacology Study Section,
following her retirement as professor of medicine, Division of Hematology and Oncology, University of Alabama at Birmingham (UAB), with secondary appointments in the Department of Pharmacology and Toxicology, Comprehensive Cancer Center, Center for AIDS Research, Arthritis and Musculoskeletal Diseases Center, Gene Therapy Center, Minority Health and Research Center, and Graduate School at UAB. Her graduate studies centered on macrophage IgG-Fc receptor biology, and postdoctoral work included macrophage-bacterial pathogen interactions and monoclonal antibody technology. Dr. Shaw’s research as a faculty member at UAB focused on immunologic aspects of hematology and cancer, both pathologic and therapeutic. Before joining NIH, Dr. Shaw served on numerous NIH review committees, including permanent member tenures on the Experimental Therapeutics 2 Study Section (ET-2, now extinct) and the Cancer Immunopathology and Immunotherapy Study Section.